- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 3, 2023
Highlights
- Total Revenue (TTM)
- $7.83M
- Gross Profit (TTM)
- -$639.50K
- EBITDA (TTM)
- -$5.21M
- Year Range
- $3.08 - $120.00
- Target Price
- $45.00
- ROA (TTM)
- -8.01%
- ROE (TTM)
- -89.85%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MLEC Performance Chart
Moolec Science SA Ordinary Shares (MLEC) is up 78.8% since the beginning of the year. At $7 per share, MLEC is trading 94.3% below its 52-week high of $120.
Loading charts...
Returns By Period
Moolec Science SA Ordinary Shares (MLEC) has returned 78.84% so far this year and -94.31% over the past 12 months.
Moolec Science SA Ordinary Shares
- 1D
- -0.29%
- 1M
- -34.14%
- YTD
- 78.84%
- 6M
- -5.73%
- 1Y
- -94.31%
- 3Y*
- -75.30%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
MLEC Monthly Returns History
Based on dividend-adjusted daily data since Jan 3, 2023, MLEC's average daily return is -0.12%, while the average monthly return is -6.88%.
Historically, 31% of months were positive and 69% were negative. The best month was Feb 2026 with a return of +104.6%, while the worst month was Aug 2025 at -59.0%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.
On a daily basis, MLEC closed higher 39% of trading days. The best single day was Jan 6, 2023 with a return of +251.3%, while the worst single day was Jan 16, 2026 at -34.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 70.20% | 104.62% | -55.49% | 90.03% | -33.07% | -9.30% | 78.84% | ||||||
| 2025 | -5.44% | -2.19% | -24.31% | 32.11% | 8.14% | -21.25% | -49.21% | -59.04% | -25.19% | -34.33% | -37.89% | -36.35% | -96.82% |
| 2024 | -19.51% | -9.09% | -23.33% | 2.90% | -17.60% | -5.99% | -12.73% | -9.36% | 1.02% | -3.37% | 2.43% | -8.05% | -67.48% |
| 2023 | -41.76% | 13.21% | -32.00% | -32.11% | 8.88% | 22.01% | -13.86% | 3.79% | -14.89% | -15.00% | 5.46% | -1.99% | -72.97% |
Benchmark Metrics
Moolec Science SA Ordinary Shares has an annualized alpha of -38.57%, beta of 0.84, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 04, 2023.
- This stock participated in 198.51% of S&P 500 Index downside but only -159.59% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -38.57%
- Beta
- 0.84
- R²
- 0.00
- Upside Capture
- -159.59%
- Downside Capture
- 198.51%
Return for Risk
Risk / Return Rank
MLEC ranks 12 for risk / return — in the bottom 12% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Moolec Science SA Ordinary Shares (MLEC) and compare them to S&P 500 Index.
| MLEC | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.46 | 2.39 | -2.84 |
Sortino ratioReturn per unit of downside risk | -1.15 | 3.25 | -4.40 |
Omega ratioGain probability vs. loss probability | 0.87 | 1.43 | -0.56 |
Calmar ratioReturn relative to maximum drawdown | -0.97 | 3.11 | -4.08 |
Martin ratioReturn relative to average drawdown | -1.12 | 14.38 | -15.50 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Moolec Science SA Ordinary Shares. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Moolec Science SA Ordinary Shares was 99.88%, occurring on Dec 24, 2025. The portfolio has not yet recovered.
The current Moolec Science SA Ordinary Shares drawdown is 99.76%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -99.88%Dec 2025 | 2y 11mo | — | 3y 4moJan 2023 - now |
2023 bear market2023 | -39.78%Jan 2023 | 1d | 1d | 2dJan 2023 - Jan 2023 |
Drawdown Indicators
| MLEC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.88% | -56.78% | -43.10% |
Max Drawdown (1Y)Largest decline over 1 year | -97.34% | -9.10% | -88.24% |
Max Drawdown (3Y)Largest decline over 3 years | -99.41% | -18.90% | -80.51% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.76% | 0.00% | -99.76% |
Average DrawdownAverage peak-to-trough decline | -91.71% | -10.72% | -80.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 84.38% | 1.97% | +82.41% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Moolec Science SA Ordinary Shares over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Moolec Science SA Ordinary Shares is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MLEC
Add Moolec Science SA Ordinary Shares to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MLEC